Kinnate Biopharma Inc.
Kinnate Biopharma Inc. (KNTE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · KNTE · as of Jun 9, 2026
Key Statistics
Explore Kinnate Biopharma Inc. Data
knte stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 33.3%
The KNTE analyst consensus is Hold, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $30.00, representing +1032.08% upside from the current price of $2.65.
Competitors & Peers
knte competitorsKNTE
AADI
ATYR
DBTX
GRAY
NGMStock Performance
Full HistoryAbout Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific gen…
what is kinnate biopharma inc. · knte stock overview · kinnate biopharma inc. company profile · who is kinnate biopharma inc. ceo · knte NASDAQ · kinnate biopharma inc. headquarters · kinnate biopharma inc. business segments
About Stock Overview & Key Data
Kinnate Biopharma Inc. (KNTE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 3, 2020. As of the latest trading session, KNTE stock price is $2.65, with a market capitalization of $125.0M. The stock has returned -6.85% over the past 12 months and +6.43% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Kinnate Biopharma Inc. stock is Hold, with an average 12-month price target of $30.00. In fiscal year 2023, Kinnate Biopharma Inc. reported revenue of — and net income of -$112.6M. For detailed data — including Kinnate Biopharma Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Kinnate Biopharma Inc. (KNTE) stock price is $2.65. The stock is traded on NASDAQ under the ticker symbol KNTE. The 52-week range is $1.04 – $7.18.